Previous 10 | Next 10 |
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which ...
Pear Therapeutics and BrightView Health have expanded a pilot program providing prescription digital therapeutics for substance use disorders. The expansion means that Pear's ( NASDAQ: PEAR ) reSET and reSET-O therapeutics are now available to BrightView patients in Kentucky,...
BrightView expands its initiative with reSET ® and reSET-O ® to patients across Kentucky, Ohio, Delaware, Massachusetts, and Virginia Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescrip...
Pear’s prescription digital therapeutics (PDTs), reSET ® and reSET-O ® , are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023 Florida Medicaid is covering reSET ® and reSET-O ® for...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:...
Pear Therapeutics ( NASDAQ: PEAR ) said that the California Department of Health Care Services (DHCS) had selected it to track and distribute incentives for the recovery incentives to treat Medi-Cal members with stimulant use disorder. The pilot program will allow eligible members...
The California Department of Healt h Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California’s Contingency Management Program, to treat Medi-Cal members with stimulant use disorder DHCS in...
Pear Therapeutics ( NASDAQ: PEAR ) has signed an agreement with COEUS Healthcare to utilize the latter's outcomes and evidence-based reimbursement adjudication platform, COEBRA, to enable value-based contracting . The pact will facilitate states' access to value-based contracting ...
COEUS’ COEBRA™ Platform to Facilitate Value and Outcomes Based Agreements for Government and Commercial Payers Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digit...
Pear Therapeutics ( NASDAQ: PEAR ) and Spero Health have extended a partnership for the former to provide the latter prescription digital therapeutics for the treatment of substance use and opioid use disorders. Shares are up 4% in premarket trading. The extended arrangeme...